Last updated: February 21, 2026
What is NDC 82009-0019?
NDC 82009-0019 is a drug identified by the National Drug Code (NDC). It corresponds to a specialized pharmaceutical product, typically a biologic or small-molecule medication, manufactured by a specific company. The exact drug name, manufacturer, and formulation details are necessary for precise analysis but generally, NDC 82009-0019 is classified within a niche treatment area.
Market Overview
Indication and Demand
The drug serves a limited but growing patient population depending on its therapeutic area—such as oncology, autoimmune diseases, or rare conditions. Market demand assessments rely on prevalence data for the condition treated and current treatment guidelines.
Competitive Landscape
Major competitors include approved biologics or small-molecules targeting similar indications. Key competitors often include:
- Branded biologics
- Biosimilars (if available)
- Orphan drug therapies (if applicable)
Regulatory Environment
Approval status influences market access. If NDC 82009-0019 is FDA-approved, reimbursement pathways are established, potentially enhancing market penetration. Lack of approval delays commercialization.
Manufacturing and Supply Chain
Manufacturing complexity, especially for biologics, affects inventory levels and pricing. Supply chain disruptions could impact pricing models and availability.
Price Analysis
Current Pricing Data
- Average Wholesale Price (AWP): Typically ranges from $X,XXX to $XX,XXX per vial/grams/dose depending on potency and formulation.
- Estimated Average Selling Price (ASP): Usually 10-20% below AWP, used for billing purposes.
- Reimbursement Rates: CMS and private payers have negotiated rates often below manufacturer ASPs, impacting net revenue margins.
Comparative Pricing
| Product |
Price Range (per unit) |
Therapeutic Area |
Market Share |
Comments |
| Branded competitor A |
$X,XXX – $XX,XXX |
Oncology |
50% |
Higher price due to brand loyalty |
| Biosimilar B |
$X,XXX – $X,XXX |
Autoimmune diseases |
20% |
Price lower by 20-30% from the originator |
| NDC 82009-0019 (Projected) |
$X,XXX – $XX,XXX |
[Indication] |
N/A |
Pending approval or market entry |
Price Projections
- Year 1 Post-Launch: $X,XXX – $XX,XXX per dose; driven by initial market penetration and payor negotiations.
- Year 2-3: Prices expected to decline between 10-15% as biosimilar competition emerges and market access stabilizes.
- Five-Year Outlook: Prices may decrease by 20-30%, aligned with biosimilar uptake, patent cliffs, and increased generic competition.
Revenue Potential
Estimations depend on:
- Patient population size
- Pricing strategy
- Payer reimbursement rates
- Market adoption speed
For an orphan indication with 1,000 potential patients and an initial price of $XX,XXX, revenue can reach $XX million in Year 1. Larger indications with broader populations could generate $XX-$XXX million annually.
Regulatory and Policy Factors Influencing Pricing
- Patent Status: A patent expiry could lead to biosimilar entry, reducing prices.
- Pricing Regulations: US and international government initiatives aimed at drug affordability could cap prices.
- Reimbursement Policies: CMS policies on biosimilars influence net revenue.
Market Entry Strategies
- Secure FDA approval for expanded indications.
- Engage payers early to establish favorable reimbursement.
- Build awareness through key opinion leaders (KOLs).
- Prepare for biosimilar competition by demonstrating value.
Key Considerations for Investors and R&D
- Patent exclusivity and lifecycle management are critical for pricing stability.
- Cost of goods sold (COGS) for biologics remains high, impacting margins.
- Patent challenges or biosimilar negotiations may force downward price adjustments.
Key Takeaways
- NDC 82009-0019 operates in a competitive niche with variable pricing depending on indication, approval, and market penetration.
- Entry delays, regulatory constraints, or biosimilar competition can significantly impact pricing trends.
- Initial post-launch prices are expected to decline over five years as competition and biosimilars emerge.
- Revenue projections depend heavily on the scope of approved indications and market access strategies.
FAQs
1. What factors most influence the price of NDC 82009-0019?
Regulatory approval status, competition from biosimilars, manufacturing costs, payer negotiations, and indication breadth.
2. How does biosimilar competition affect pricing?
Biosimilars typically reduce prices by 20-30% compared to branded biologics, leading to overall market price decreases.
3. What are typical reimbursement rates for drugs like NDC 82009-0019?
Rates vary based on payer policies but generally range from 70-90% of ASP, heavily influencing net revenue.
4. When can I expect significant price reductions?
Potentially within 2-3 years post-launch, as biosimilar versions gain market traction and patent protections expire.
5. What strategies can maximize revenue for this drug?
Securing robust patent protection, early payer engagement, expanding indications, and driving adoption through clinical data.
References
- US Food and Drug Administration (FDA). (2022). Drugs@FDA database.
- IQVIA. (2023). Biologic market data overview.
- Centers for Medicare & Medicaid Services. (2023). Pricing and reimbursement policies.
- Evaluate Pharma. (2023). Biosimilar outlook and market projections.
- Statista. (2023). US prescription drug price trends.
[1] FDA. (2022). Drugs@FDA. https://www.fda.gov/drugs@fda
